Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 1Active not recruiting 1

Sponsor Class

NETWORK 2

Study Type

Interventional 2

Sponsor

Conditions

Breast Neoplasms 213Carcinoma, Non-Small-Cell Lung 148Lung Neoplasms 128Lymphoma 119Prostatic Neoplasms 115Leukemia 102Ovarian Neoplasms 100Central Nervous System Neoplasms 95Precursor Cell Lymphoblastic Leukemia-Lymphoma 89Colorectal Neoplasms 89Head and Neck Neoplasms 87Sarcoma 84Multiple Myeloma 80Squamous Cell Carcinoma of Head and Neck 73Rectal Neoplasms 62Leukemia, Myeloid, Acute 62Carcinoma, Ovarian Epithelial 61Uterine Cervical Neoplasms 60Neoplasm Metastasis 59Brain Neoplasms 57Colonic Neoplasms 56Fallopian Tube Neoplasms 53Astrocytoma 53Lymphoma, Large B-Cell, Diffuse 50Glioblastoma 49Burkitt Lymphoma 47Urinary Bladder Neoplasms 46Neuroblastoma 44Melanoma 44Hodgkin Disease 44

Interventions

tremelimumab 1temsirolimus 1durvalumab 1Sunitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NETWORK × Interventional × Advanced Rare Tumours × Clear all
NCT01396408 2026-03-27

A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours

Canadian Cancer Trials Group

Phase 2 Active not recruiting
137 enrolled

Advanced Rare Tumours

NCT02879162 2025-03-07

Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours

Canadian Cancer Trials Group

Phase 2 Completed
140 enrolled 9 charts

Advanced Rare Tumours

Data powered by HemOnc (CC BY 4.0) Colophon âš¡